Financhill
Sell
47

TMO Quote, Financials, Valuation and Earnings

Last price:
$422.00
Seasonality move :
1.19%
Day range:
$422.04 - $430.50
52-week range:
$385.46 - $627.88
Dividend yield:
0.39%
P/E ratio:
24.95x
P/S ratio:
3.79x
P/B ratio:
3.25x
Volume:
2.8M
Avg. volume:
2.7M
1-year change:
-22.4%
Market cap:
$160.6B
Revenue:
$42.9B
EPS (TTM):
$17.05

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TMO
Thermo Fisher Scientific
$10.7B $5.23 2.42% 30.64% $550.52
APDN
Applied DNA Sciences
$1.3M -$37.50 27.47% -98.87% --
FONR
Fonar
-- -- -- -- --
PRPH
ProPhase Labs
$3.6M -$0.15 3.99% -50% $13.80
SHC
Sotera Health
$275.8M $0.17 -0.17% 478.43% $14.50
XWEL
XWELL
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TMO
Thermo Fisher Scientific
$425.34 $550.52 $160.6B 24.95x $0.43 0.39% 3.79x
APDN
Applied DNA Sciences
$5.24 -- $2.7M -- $0.00 0% 0.06x
FONR
Fonar
$16.31 -- $102.7M 13.05x $0.00 0% 1.01x
PRPH
ProPhase Labs
$0.43 $13.80 $17.7M -- $0.00 0% 2.31x
SHC
Sotera Health
$11.61 $14.50 $3.3B 145.13x $0.00 0% 2.99x
XWEL
XWELL
$0.99 -- $5.2M -- $0.00 0% 0.15x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TMO
Thermo Fisher Scientific
40.91% 0.769 18.19% 1.20x
APDN
Applied DNA Sciences
-- 5.076 -- 3.97x
FONR
Fonar
-- 1.699 -- 9.69x
PRPH
ProPhase Labs
22.08% -3.124 25.51% 0.84x
SHC
Sotera Health
84.28% 0.097 67.08% 2.02x
XWEL
XWELL
-- 0.204 -- 1.41x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TMO
Thermo Fisher Scientific
$4.2B $1.8B 7.88% 13.49% 18.56% $361M
APDN
Applied DNA Sciences
$370.9K -$3.5M -84.02% -84.02% -352.03% -$3.4M
FONR
Fonar
$12.1M $3.7M 5.32% 5.33% 15.23% $2.5M
PRPH
ProPhase Labs
$526K -$3.7M -101.67% -144.22% -289.24% -$3.4M
SHC
Sotera Health
$135.4M $57M 0.94% 5.79% 10.24% $35.6M
XWEL
XWELL
$1.3M -$3.2M -153.74% -153.74% -64.9% -$4.6M

Thermo Fisher Scientific vs. Competitors

  • Which has Higher Returns TMO or APDN?

    Applied DNA Sciences has a net margin of 14.54% compared to Thermo Fisher Scientific's net margin of -336%. Thermo Fisher Scientific's return on equity of 13.49% beat Applied DNA Sciences's return on equity of -84.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    TMO
    Thermo Fisher Scientific
    40.86% $3.98 $83.7B
    APDN
    Applied DNA Sciences
    37.71% -$230.25 $10.2M
  • What do Analysts Say About TMO or APDN?

    Thermo Fisher Scientific has a consensus price target of $550.52, signalling upside risk potential of 29.43%. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 429289.1%. Given that Applied DNA Sciences has higher upside potential than Thermo Fisher Scientific, analysts believe Applied DNA Sciences is more attractive than Thermo Fisher Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    TMO
    Thermo Fisher Scientific
    17 6 0
    APDN
    Applied DNA Sciences
    0 1 0
  • Is TMO or APDN More Risky?

    Thermo Fisher Scientific has a beta of 0.769, which suggesting that the stock is 23.079% less volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.068, suggesting its less volatile than the S&P 500 by 93.226%.

  • Which is a Better Dividend Stock TMO or APDN?

    Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.39%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TMO or APDN?

    Thermo Fisher Scientific quarterly revenues are $10.4B, which are larger than Applied DNA Sciences quarterly revenues of $983.4K. Thermo Fisher Scientific's net income of $1.5B is higher than Applied DNA Sciences's net income of -$3.3M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 24.95x while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 3.79x versus 0.06x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TMO
    Thermo Fisher Scientific
    3.79x 24.95x $10.4B $1.5B
    APDN
    Applied DNA Sciences
    0.06x -- $983.4K -$3.3M
  • Which has Higher Returns TMO or FONR?

    Fonar has a net margin of 14.54% compared to Thermo Fisher Scientific's net margin of 9.23%. Thermo Fisher Scientific's return on equity of 13.49% beat Fonar's return on equity of 5.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    TMO
    Thermo Fisher Scientific
    40.86% $3.98 $83.7B
    FONR
    Fonar
    44.52% $0.37 $160.3M
  • What do Analysts Say About TMO or FONR?

    Thermo Fisher Scientific has a consensus price target of $550.52, signalling upside risk potential of 29.43%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Thermo Fisher Scientific has higher upside potential than Fonar, analysts believe Thermo Fisher Scientific is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    TMO
    Thermo Fisher Scientific
    17 6 0
    FONR
    Fonar
    0 0 0
  • Is TMO or FONR More Risky?

    Thermo Fisher Scientific has a beta of 0.769, which suggesting that the stock is 23.079% less volatile than S&P 500. In comparison Fonar has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.238%.

  • Which is a Better Dividend Stock TMO or FONR?

    Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.39%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TMO or FONR?

    Thermo Fisher Scientific quarterly revenues are $10.4B, which are larger than Fonar quarterly revenues of $27.2M. Thermo Fisher Scientific's net income of $1.5B is higher than Fonar's net income of $2.5M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 24.95x while Fonar's PE ratio is 13.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 3.79x versus 1.01x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TMO
    Thermo Fisher Scientific
    3.79x 24.95x $10.4B $1.5B
    FONR
    Fonar
    1.01x 13.05x $27.2M $2.5M
  • Which has Higher Returns TMO or PRPH?

    ProPhase Labs has a net margin of 14.54% compared to Thermo Fisher Scientific's net margin of -209.38%. Thermo Fisher Scientific's return on equity of 13.49% beat ProPhase Labs's return on equity of -144.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    TMO
    Thermo Fisher Scientific
    40.86% $3.98 $83.7B
    PRPH
    ProPhase Labs
    36.76% $0.11 $19.4M
  • What do Analysts Say About TMO or PRPH?

    Thermo Fisher Scientific has a consensus price target of $550.52, signalling upside risk potential of 29.43%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3145.53%. Given that ProPhase Labs has higher upside potential than Thermo Fisher Scientific, analysts believe ProPhase Labs is more attractive than Thermo Fisher Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    TMO
    Thermo Fisher Scientific
    17 6 0
    PRPH
    ProPhase Labs
    0 0 0
  • Is TMO or PRPH More Risky?

    Thermo Fisher Scientific has a beta of 0.769, which suggesting that the stock is 23.079% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.412, suggesting its less volatile than the S&P 500 by 141.195%.

  • Which is a Better Dividend Stock TMO or PRPH?

    Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.39%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TMO or PRPH?

    Thermo Fisher Scientific quarterly revenues are $10.4B, which are larger than ProPhase Labs quarterly revenues of $1.4M. Thermo Fisher Scientific's net income of $1.5B is higher than ProPhase Labs's net income of $4M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 24.95x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 3.79x versus 2.31x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TMO
    Thermo Fisher Scientific
    3.79x 24.95x $10.4B $1.5B
    PRPH
    ProPhase Labs
    2.31x -- $1.4M $4M
  • Which has Higher Returns TMO or SHC?

    Sotera Health has a net margin of 14.54% compared to Thermo Fisher Scientific's net margin of -5.21%. Thermo Fisher Scientific's return on equity of 13.49% beat Sotera Health's return on equity of 5.79%.

    Company Gross Margin Earnings Per Share Invested Capital
    TMO
    Thermo Fisher Scientific
    40.86% $3.98 $83.7B
    SHC
    Sotera Health
    53.21% -$0.05 $2.6B
  • What do Analysts Say About TMO or SHC?

    Thermo Fisher Scientific has a consensus price target of $550.52, signalling upside risk potential of 29.43%. On the other hand Sotera Health has an analysts' consensus of $14.50 which suggests that it could grow by 24.89%. Given that Thermo Fisher Scientific has higher upside potential than Sotera Health, analysts believe Thermo Fisher Scientific is more attractive than Sotera Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    TMO
    Thermo Fisher Scientific
    17 6 0
    SHC
    Sotera Health
    3 3 0
  • Is TMO or SHC More Risky?

    Thermo Fisher Scientific has a beta of 0.769, which suggesting that the stock is 23.079% less volatile than S&P 500. In comparison Sotera Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock TMO or SHC?

    Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.39%. Sotera Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. Sotera Health pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TMO or SHC?

    Thermo Fisher Scientific quarterly revenues are $10.4B, which are larger than Sotera Health quarterly revenues of $254.5M. Thermo Fisher Scientific's net income of $1.5B is higher than Sotera Health's net income of -$13.3M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 24.95x while Sotera Health's PE ratio is 145.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 3.79x versus 2.99x for Sotera Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TMO
    Thermo Fisher Scientific
    3.79x 24.95x $10.4B $1.5B
    SHC
    Sotera Health
    2.99x 145.13x $254.5M -$13.3M
  • Which has Higher Returns TMO or XWEL?

    XWELL has a net margin of 14.54% compared to Thermo Fisher Scientific's net margin of -67.19%. Thermo Fisher Scientific's return on equity of 13.49% beat XWELL's return on equity of -153.74%.

    Company Gross Margin Earnings Per Share Invested Capital
    TMO
    Thermo Fisher Scientific
    40.86% $3.98 $83.7B
    XWEL
    XWELL
    18.78% -$1.00 $3.4M
  • What do Analysts Say About TMO or XWEL?

    Thermo Fisher Scientific has a consensus price target of $550.52, signalling upside risk potential of 29.43%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 607.07%. Given that XWELL has higher upside potential than Thermo Fisher Scientific, analysts believe XWELL is more attractive than Thermo Fisher Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    TMO
    Thermo Fisher Scientific
    17 6 0
    XWEL
    XWELL
    0 0 0
  • Is TMO or XWEL More Risky?

    Thermo Fisher Scientific has a beta of 0.769, which suggesting that the stock is 23.079% less volatile than S&P 500. In comparison XWELL has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.424%.

  • Which is a Better Dividend Stock TMO or XWEL?

    Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.39%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TMO or XWEL?

    Thermo Fisher Scientific quarterly revenues are $10.4B, which are larger than XWELL quarterly revenues of $7M. Thermo Fisher Scientific's net income of $1.5B is higher than XWELL's net income of -$4.7M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 24.95x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 3.79x versus 0.15x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TMO
    Thermo Fisher Scientific
    3.79x 24.95x $10.4B $1.5B
    XWEL
    XWELL
    0.15x -- $7M -$4.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
77
VBTX alert for Jul 15

Veritex Holdings [VBTX] is down 0.88% over the past day.

Buy
72
MNPR alert for Jul 15

Monopar Therapeutics [MNPR] is down 1.28% over the past day.

Buy
56
NBIS alert for Jul 15

Nebius Group NV [NBIS] is up 5.14% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock